ReviewOncoTargets and therapy2017
Intrahepatic cholangiocarcinoma: current perspectives.
Review in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 3 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Long-Term Survivor of Intrahepatic Cholangiocarcinoma for over 18 Years: Case Study with Longitudinal Histo-molecular and Tumor Immune Microenvironment Characterization and Systematic Review of the Literature.Journal of gastrointestinal cancer · 2024Pooled it
- Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.BMC gastroenterology · 2023Pooled it
- Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2022Pooled it
- Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer.Technology in cancer research & treatment · 2018Trial
- Cholangioblastic variant of intrahepatic cholangiocarcinoma in a young adult with situs inversus totalis.BMJ case reports · 2026Article
- Pictorial review of abdominopelvic diseases with elevated alpha-fetoprotein levels.Abdominal radiology (New York) · 2026Review
- Effect of Case Discussion with Expert Centers on Treatment Outcome of Intrahepatic Cholangiocarcinoma.Annals of surgical oncology · 2026Article
- Facility Type Predicts Completeness of Oncologic Resection and Survival in Biliary Tract Cancers.Journal of gastrointestinal cancer · 2026Article
- IL-33 released during liver resection facilitates intrahepatic cholangiocarcinoma growth via cytokine secretion in cancer-associated fibroblasts.British journal of cancer · 2026Article
- Whole Transcriptome Sequencing Analyzes the Interactions of mRNAs and ncRNAs in Cholangiocarcinoma.Cancer medicine · 2025Article
- Prognostic impact of abdominal aortic calcification in patients who underwent hepatectomy for intrahepatic cholangiocarcinoma.Surgery today · 2025Article
- Age and Tumor Stage Interplay in Intrahepatic Cholangiocarcinoma: Prognostic Factors, Mortality Trends, and Therapeutic Implications from a SEER-Based Analysis.Diseases (Basel, Switzerland) · 2025Article
- The role of lactylation in tumor growth and cancer progression.Frontiers in oncology · 2025Review
- SiameseNet based on multiple instance learning for accurate identification of the histological grade of ICC tumors.Frontiers in oncology · 2025Article
- Article
- Single-cell analysis defines LGALS1+ fibroblasts that promote proliferation and migration of intrahepatic cholangiocarcinoma.Journal of molecular cell biology · 2024Article
- Review
- A Machine Learning-Based Clustering Using Radiomics of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for the Prediction of Prognosis in Patients with Intrahepatic Cholangiocarcinoma.Diagnostics (Basel, Switzerland) · 2024Article
- Changes in the epidemiological trends of primary liver cancer in the Asia-Pacific region.Scientific reports · 2024Article
- Current interventional options for palliative care for patients with advanced-stage cholangiocarcinoma.World journal of clinical oncology · 2024Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy arising from the liver. ICC makes up about 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals. Histologically, the majority of ICCs are adenocarcinomas. Only a minority of patients (15%) present with resectable disease, with a median survival of less than 3 years. Multidisciplinary management of ICC is complicated by large differences in disease course for individual patients both across and within tumor stages. Risk models and nomograms have been developed to more accurately predict survival of individual patients based on clinical parameters. Predictive risk factors are necessary to improve patient selection for systemic treatments. Molecular differences between tumors, such as in the epidermal growth factor receptor status, are promising, but their clinical applicability should be validated. For patients with locally advanced disease, several treatment strategies are being evaluated. Both hepatic arterial infusion chemotherapy with floxuridine and yttrium-90 embolization aim to downstage locally advanced ICC. Selected patients have resectable disease after downstaging, and other patients might benefit because of postponing widespread dissemination and biliary obstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.